NCT03862807 - Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

October 6, 2020

Study Completion Date

October 20, 2020

Conditions

Amyloidosis, FamilialTransthyretin Amyloidosis

Interventions

DRUG

Patisiran

Patisiran was administered via IV infusion.

Trial Locations (9)

Clinical Trial Site, Créteil

Clinical Trial Site, Le Kremlin-Bicêtre

Clinical Trial Site, Münster

Clinical Trial Site, Messina

Clinical Trial Site, Porto

Clinical Trial Site, Barcelona

Clinical Trial Site, Huelva

Clinical Trial Site, Umeå

Clinical Trial Site, London